Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity

Molecular Biology Reports

Volumn 40, Issue 3, 2013, Pages 2697-2704

  Belo, Vanessa A ^a   Luizon, Marcelo R ^a   Carneiro, Patrícia C ^a   Gomes, Valéria A ^b   Lacchini, Riccardo ^a   Lanna, Carla M M ^c   Souza Costa, Debora C ^c   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Childhood obesity; Hypertension; Matrix metalloproteinase 2; Polymorphisms

Indexed keywords

GELATINASE A;

ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE; GENE ACTIVITY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MMP 2 GENE; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; ZYMOGRAPHY;

ADOLESCENT; ALLELES; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; METABOLIC SYNDROME X; PEDIATRIC OBESITY; RISK FACTORS;

EID: 84878422328     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2356-7     Document Type: Article

References (52)

1. Wang G, Dietz WH (2002) Economic burden of obesity in youths aged 6 to 17 years: 1979-1999. Pediatrics 109(5):E81-E81
2. Kotchen TA (2010) Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 23(11):1170-1178
3. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, Robinson TN, Scott BJ, St Jeor S, Williams CL (2005) Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 111(15):1999-2012
4. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444(7121):875-880
5. Lijnen HR (2008) Angiogenesis and obesity. Cardiovasc Res 78(2):286-293
6. Van Hul M, Lijnen HR (2008) A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 6(7):1198-1206
7. Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L, Collen D (2002) Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol 22(3):374-379
8. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562-573
9. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE (2009) Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 42(10-11):984-990
10. Berg G, Miksztowicz V, Schreier L (2011) Metalloproteinases in metabolic syndrome. Clin Chim Acta 412(19-20):1731-1739
11. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB (2005) Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25(2):372
12. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198(2):320-331
13. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, Tanus-Santos JE, Gerlach RF (2010) Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 16(7):599-608
14. Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, Cicero AF (2009) Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 32(2):E124-E132
15. Miksztowicz V, Muzzio ML, Royer M, Prada M, Wikinski R, Schreier L, Berg G (2008) Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism 57(11):1493-1496
16. Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, D'Angelo A (2007) Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium 14(4-5):175-183
17. Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Piccinni MN, Peros E, Geroldi D, Fogari E, D'Angelo A (2007) Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 14(1):45-51
18. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF (2010) Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res 79(2):144-149
19. Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276(10):7549-7558
20. Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM, Oliveira SA, Vicente AM (2010) Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet 11:40
21. Singh R, Srivastava P, Srivastava A, Mittal RD (2010) Matrix metalloproteinase (MMP-9 and MMP-2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant 25(10):3393-3401
22. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64(20):7622-7628
23. Han DH, Kim SK, Kang S, Choe BK, Kim KS, Chung JH (2008) Matrix metallopeptidase 2 gene polymorphism is associated with obesity in Korean population. Korean J Physiol Pharmacol 12(3):125-129
24. Morgan AR, Han DY, Thompson JM, Mitchell EA, Ferguson LR (2011) Analysis of MMP2 promoter polymorphisms in childhood obesity. BMC Res Notes 4:253
25. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W Jr, Tanus-Santos JE (2012) Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 26(3):171-177
26. Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Duarte G, Tanus-Santos JE (2012) Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol 92(2):217-221
27. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000) CDC growth charts: United States. Adv Data 314:1-27
28. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996). Pediatrics 98 (4 Pt 1):649-658
29. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH (2003) Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157(8):821-827
30. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350(23):2362-2374
31. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C (2005) Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115(4):e500-e503
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419
33. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE (2006) Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365(1-2):183-187
34. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40(1-2):119-123
35. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344(1):147-149
36. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38(5):410-414
37. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989
38. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF (2008) Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4):219-224
39. Glowinska-Olszewska B, Urban M, Florys B (2006) Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12(3):179-183
40. Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251-262
41. Fernandez-Patron C, Radomski MW, Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85(10):906-911
42. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF (2006) Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13(3):227-231
43. 2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 17(3):273-276
44. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113(17):2089-2096
45. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE (2006) Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47(1):117-122
46. Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C, Gerlach RF, Tanus-Santos JE (2011) Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 109(2):130-137
47. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R, Tavella M, Schreier L, Berg GA (2009) Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 40(1):48-53
48. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC, Ferraz KC, Tanus-Santos JE (2012) Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36(1):69-75
49. Van Hul M, Piccard H, Lijnen HR (2010) Gelatinase B (MMP-9) deficiency does not affect murine adipose tissue development. Thromb Haemost 104(1):165-171
50. Goncalves FM, Martins-Oliveira A, Lacchini R, Belo VA, Speciali JG, Dach F, Tanus-Santos JE (2013) Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura. Gene 512(1):35-40
51. Marson BP, Lacchini R, Belo V, Dickel S, da Costa BP, Poli de Figueiredo CE, Tanus-Santos JE (2012) Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease. Am J Nephrol 35(3):209-215
52. Jacob-Ferreira AL, Lacchini R, Gerlach RF, Passos CJ, Barbosa F Jr, Tanus-Santos JE (2011) A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. Sci Total Environ 409(20):4242-4246